The world should aim to have vaccines which reduce malaria cases by 75 percent, and are capable of eliminating malaria, licensed by 2030, according to the updated 2013 Malaria Vaccine Technology Roadmap, launched today. This new target comes in addition to the original 2006 Roadmap's goal of having a licensed vaccine against Plasmodium falciparum malaria, the most deadly form of the disease, for children under 5 years of age in sub-Saharan Africa by 2015.
"Safe, effective, affordable vaccines could play a critical role in defeating malaria," said Dr Robert D. Newman, Director of the World Health Organization's (WHO) Global Malaria Programme. "Despite all the recent progress countries have made, and despite important innovations in diagnostics, drugs and vector control, the global burden of malaria remains unacceptably high."
The most recent figures by WHO indicate that malaria causes an estimated 660,000 deaths each year from 219 million cases of illness. Scale-up of WHO recommended malaria control measures has been associated with a 26 percent reduction in the global malaria death rate over the last decade. Effective malaria vaccines could be an important complement to existing measures, if they can be successfully developed.
Final results from Phase III trials of the most advanced vaccine candidate, RTS,S/AS01, will be available by 2015. Depending on the final trial results, and depending on the outcome of the regulatory review by the European Medicines Agency, a WHO recommendation for use and subsequent prequalification of this first vaccine could occur in late 2015.
The new roadmap, launched today at the annual conference of the American Society of Tropical Medicine & Hygiene in Washington, DC and also announced in a letter published in The Lancet, aims to identify where additional funding and activities will be particularly key in developing second generation malaria vaccines both for protection against malaria disease and for malaria elimination. These include next-generation vaccines that target both Plasmodium falciparum and Plasmodium vivax species of malaria.
"The new vaccines should show at least 75 percent efficacy against clinical malaria, be suitable for use in in all malaria-endemic areas, and be licensed by 2030," says Dr Jean-Marie Okwo Bele, Director of WHO's Department of Immunization, Vaccines and Biologicals. "The roadmap also sets a target for malaria vaccines that reduce transmission of the parasite."
The 2013 Malaria Vaccine Technology Roadmap cites several reasons for the update, among them changing malaria epidemiology associated with the successful scale-up of malaria control measures in the last decade, a renewed focus on malaria elimination and eradication in addition to the ongoing need to sustain malaria control activities, and new technological innovations since 2006 including promising early work on so-called transmission-blocking malaria vaccines.
WHO lists 27 malaria vaccine candidates currently in clinical trials, with most in early stages of testing; RTS,S/AS01 is the only one currently in late-stage development.
The roadmap's vision centres on developing safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent disease and death and prevent transmission to enable malaria eradication, and is built around two strategic goals:
- Development of malaria vaccines with protective efficacy of at least 75 percent against clinical malaria suitable for administration to appropriate at-risk groups in malaria-endemic areas.
- Development of malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings. Vaccines to reduce transmission should be suitable for administration in mass campaigns.
Explore further: Cross-species malaria immunity induced by chemically attenuated parasites
More information: www.malariavaccine.org/malvac-roadmap.php;
Medical Xpress on facebook
Related Stories
Cross-species malaria immunity induced by chemically attenuated parasites
Jul 01, 2013
Malaria, a mosquito-born infectious disease, kills over 600,000 people every year. Research has focused on the development of a vaccine to prevent the disease; however, many malaria vaccines targeting parasite antigens have ...
Travelers push US malaria count highest in 40 yrs
Oct 31, 2013
U.S. malaria cases are at their highest level in four decades, mostly from Americans bringing home an unwelcome souvenir from their travels.
Malaria vaccine candidate reduces disease over 18 months of follow-up in phase 3 children's study
Oct 07, 2013
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 ...
$450 mn needed to tackle 'grave' malaria threat, WHO says
Oct 24, 2013
Hundreds of millions of dollars are needed to stop a deadly form of drug-resistant malaria jumping from Southeast Asia to the rest of the world, the World Health Organisation said Thursday.
Eliminating malaria has longlasting benefits for many countries
Feb 21, 2013
Many nations battling malaria face an economic dilemma: spend money indefinitely to control malaria transmission or commit additional resources to eliminate transmission completely.
Recommended for you
Kuwait reports second MERS virus case
5 hours ago
Kuwait has reported its second case of the deadly MERS coronavirus for a man who just returned from abroad, the health ministry said.
Women with asthma could face a delay in becoming pregnant
14 hours ago
Women with asthma could take longer to conceive, according to new research.
National project tracks the spread of UK flu and extends monitoring to schools
14 hours ago
Are Northerners really more likely to get flu? Does regular exercise help you to recover faster? And what impact will the new childhood flu vaccinations have on the spread of the virus in schools? These are just some of the ...
Taiwan scientists report first case of new bird flu virus in humans
15 hours ago
Scientists from Taiwan report on the world's first confirmed case of human infection with a wild avian influenza A H6N1 virus in The Lancet Respiratory Medicine.
Urine tests don't always confirm urinary infections, study finds
15 hours ago
(HealthDay)—When doctors suspect a patient has a urinary tract infection, they often request a urine sample so they can test for the presence of bacteria. Now, new research suggests this step may be unnecessary.
Time to tackle cryptosporidiosis: Scientists call for crypto cure
15 hours ago
A recent study involving more than 22,000 children in Africa and Asia revealed that the protozoan parasite Cryptosporidium is one of four pathogens responsible for the largest part of severe diarrhea in inf ...
User comments
© Medical Xpress 2011-2013, Phys.org network
The world should aim to have vaccines which reduce malaria cases by 75 percent, and are capable of eliminating malaria, licensed by 2030, according to the updated 2013 Malaria Vaccine Technology Roadmap, launched today. This new target comes in addition to the original 2006 Roadmap's goal of having a licensed vaccine against Plasmodium falciparum malaria, the most deadly form of the disease, for children under 5 years of age in sub-Saharan Africa by 2015.
"Safe, effective, affordable vaccines could play a critical role in defeating malaria," said Dr Robert D. Newman, Director of the World Health Organization's (WHO) Global Malaria Programme. "Despite all the recent progress countries have made, and despite important innovations in diagnostics, drugs and vector control, the global burden of malaria remains unacceptably high."
The most recent figures by WHO indicate that malaria causes an estimated 660,000 deaths each year from 219 million cases of illness. Scale-up of WHO recommended malaria control measures has been associated with a 26 percent reduction in the global malaria death rate over the last decade. Effective malaria vaccines could be an important complement to existing measures, if they can be successfully developed.
Final results from Phase III trials of the most advanced vaccine candidate, RTS,S/AS01, will be available by 2015. Depending on the final trial results, and depending on the outcome of the regulatory review by the European Medicines Agency, a WHO recommendation for use and subsequent prequalification of this first vaccine could occur in late 2015.
The new roadmap, launched today at the annual conference of the American Society of Tropical Medicine & Hygiene in Washington, DC and also announced in a letter published in The Lancet, aims to identify where additional funding and activities will be particularly key in developing second generation malaria vaccines both for protection against malaria disease and for malaria elimination. These include next-generation vaccines that target both Plasmodium falciparum and Plasmodium vivax species of malaria.
"The new vaccines should show at least 75 percent efficacy against clinical malaria, be suitable for use in in all malaria-endemic areas, and be licensed by 2030," says Dr Jean-Marie Okwo Bele, Director of WHO's Department of Immunization, Vaccines and Biologicals. "The roadmap also sets a target for malaria vaccines that reduce transmission of the parasite."
The 2013 Malaria Vaccine Technology Roadmap cites several reasons for the update, among them changing malaria epidemiology associated with the successful scale-up of malaria control measures in the last decade, a renewed focus on malaria elimination and eradication in addition to the ongoing need to sustain malaria control activities, and new technological innovations since 2006 including promising early work on so-called transmission-blocking malaria vaccines.
WHO lists 27 malaria vaccine candidates currently in clinical trials, with most in early stages of testing; RTS,S/AS01 is the only one currently in late-stage development.
The roadmap's vision centres on developing safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent disease and death and prevent transmission to enable malaria eradication, and is built around two strategic goals:
- Development of malaria vaccines with protective efficacy of at least 75 percent against clinical malaria suitable for administration to appropriate at-risk groups in malaria-endemic areas.
- Development of malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings. Vaccines to reduce transmission should be suitable for administration in mass campaigns.
Explore further: Cross-species malaria immunity induced by chemically attenuated parasites
More information: www.malariavaccine.org/malvac-roadmap.php;
Medical Xpress on facebook
Related Stories
Cross-species malaria immunity induced by chemically attenuated parasites
Jul 01, 2013
Malaria, a mosquito-born infectious disease, kills over 600,000 people every year. Research has focused on the development of a vaccine to prevent the disease; however, many malaria vaccines targeting parasite antigens have ...
Travelers push US malaria count highest in 40 yrs
Oct 31, 2013
U.S. malaria cases are at their highest level in four decades, mostly from Americans bringing home an unwelcome souvenir from their travels.
Malaria vaccine candidate reduces disease over 18 months of follow-up in phase 3 children's study
Oct 07, 2013
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 ...
$450 mn needed to tackle 'grave' malaria threat, WHO says
Oct 24, 2013
Hundreds of millions of dollars are needed to stop a deadly form of drug-resistant malaria jumping from Southeast Asia to the rest of the world, the World Health Organisation said Thursday.
Eliminating malaria has longlasting benefits for many countries
Feb 21, 2013
Many nations battling malaria face an economic dilemma: spend money indefinitely to control malaria transmission or commit additional resources to eliminate transmission completely.
Recommended for you
Kuwait reports second MERS virus case
5 hours ago
Kuwait has reported its second case of the deadly MERS coronavirus for a man who just returned from abroad, the health ministry said.
Women with asthma could face a delay in becoming pregnant
14 hours ago
Women with asthma could take longer to conceive, according to new research.
National project tracks the spread of UK flu and extends monitoring to schools
14 hours ago
Are Northerners really more likely to get flu? Does regular exercise help you to recover faster? And what impact will the new childhood flu vaccinations have on the spread of the virus in schools? These are just some of the ...
Taiwan scientists report first case of new bird flu virus in humans
15 hours ago
Scientists from Taiwan report on the world's first confirmed case of human infection with a wild avian influenza A H6N1 virus in The Lancet Respiratory Medicine.
Urine tests don't always confirm urinary infections, study finds
15 hours ago
(HealthDay)—When doctors suspect a patient has a urinary tract infection, they often request a urine sample so they can test for the presence of bacteria. Now, new research suggests this step may be unnecessary.
Time to tackle cryptosporidiosis: Scientists call for crypto cure
15 hours ago
A recent study involving more than 22,000 children in Africa and Asia revealed that the protozoan parasite Cryptosporidium is one of four pathogens responsible for the largest part of severe diarrhea in inf ...
User comments
© Medical Xpress 2011-2013, Phys.org network
No comments:
Post a Comment